BioNTech, Fosun Pharma Expected to Supply 10 Million COVID-19 Vaccine Doses in China
BioNTech and Fosun Pharma have announced the first COVID-19 supply deal in China for up to 10 million doses of their mRNA-based vaccine.
China-based Fosun signed a letter of intent with Jacobson Pharma yesterday for the doses to be distributed to Hong Kong and Macau. Terms of the deal were not disclosed.
BioNTech and Fosun Pharma began working together in March to develop and commercialize their vaccine in China. A phase 1 trial of the vaccine candidate, BNT162b1, was launched in China earlier this month.